评估接受口服药物治疗的甲状腺机能亢进猫的主人潜在的甲巯咪唑暴露情况。
Evaluation of potential thiamazole exposure of owners of orally treated hyperthyroid cats.
机构信息
Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Laboratory of Chemical Analysis, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
出版信息
J Feline Med Surg. 2022 Jun;24(6):e138-e141. doi: 10.1177/1098612X221091738. Epub 2022 Apr 26.
OBJECTIVES
The objective of this study was to evaluate the presence of traces of thiamazole in the urine of owners of hyperthyroid cats treated with antithyroid drugs.
METHODS
Urine was collected from 24 owners of hyperthyroid cats, five human patients treated with thiamazole and five healthy humans without any contact with antithyroid drugs. All owners of hyperthyroid cats were asked to fill out a questionnaire. Urine of hyperthyroid cats was collected by spontaneous micturition. All urine samples were stored at -20°C until analysis by ultra-high-performance liquid chromatography coupled to high-resolution quadrupole Orbitrap mass spectrometry.
RESULTS
These owners were assessed to have a lot of contact with their cat. Adherence to antithyroid medication handling guidelines was rather poor. High concentrations of thiamazole were detected in all feline samples (median concentration 2818 ng/ml; range 104-15,127) and in the urine of all human patients treated with thiamazole (median concentration 4153 ng/ml; range 1826-5009). No thiamazole was detected in the urine of owners of hyperthyroid cats (limit of detection 3.88 ng/ml; limit of quantification 11.75 ng/ml).
CONCLUSIONS AND RELEVANCE
The results regarding the potential exposure of owners of hyperthyroid cats to antithyroid drugs are reassuring. Nevertheless, prudence is still warranted when administering antithyroid drugs. Whether these results can be extrapolated to the use of transdermal application requires further investigation.
目的
本研究旨在评估接受抗甲状腺药物治疗的甲状腺功能亢进猫的主人的尿液中是否存在他巴唑痕迹。
方法
收集了 24 名甲状腺功能亢进猫主人、5 名接受他巴唑治疗的人类患者和 5 名未接触过抗甲状腺药物的健康人类的尿液。所有甲状腺功能亢进猫的主人都被要求填写一份问卷。通过自发性排尿收集甲状腺功能亢进猫的尿液。所有尿液样本均在-20°C 下储存，直到通过超高效液相色谱-高分辨率四极杆轨道阱质谱联用进行分析。
结果
这些主人被评估为与他们的猫有很多接触。对抗甲状腺药物处理指南的依从性相当差。在所有猫样本中均检测到大量的他巴唑（中位数浓度为 2818ng/ml；范围为 104-15127），并且在所有接受他巴唑治疗的人类患者的尿液中均检测到（中位数浓度为 4153ng/ml；范围为 1826-5009）。在甲状腺功能亢进猫的主人的尿液中未检测到他巴唑（检测限 3.88ng/ml；定量限 11.75ng/ml）。
结论和相关性
关于甲状腺功能亢进猫的主人接触抗甲状腺药物的潜在风险的结果令人放心。然而，在给予抗甲状腺药物时仍需谨慎。这些结果是否可以推广到透皮应用的使用，需要进一步研究。
Zotero 插件